Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor

Background: Accumulating evidence suggests that the receptor binding domain (RBD) of the SARS-CoV-2 Omicron variant has several times more binding affinity to the human angiotensin-converting enzyme 2 (ACE2) receptor compared to the RBD of the original Covid-19 strain. This increased binding affinit...

Full description

Saved in:
Bibliographic Details
Main Authors: Acharya Balkrishna, Rishabh Dev, Sandeep Kumar, Anurag Varshney
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Phytomedicine Plus
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667031324001799
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823861174372925440
author Acharya Balkrishna
Rishabh Dev
Sandeep Kumar
Anurag Varshney
author_facet Acharya Balkrishna
Rishabh Dev
Sandeep Kumar
Anurag Varshney
author_sort Acharya Balkrishna
collection DOAJ
description Background: Accumulating evidence suggests that the receptor binding domain (RBD) of the SARS-CoV-2 Omicron variant has several times more binding affinity to the human angiotensin-converting enzyme 2 (ACE2) receptor compared to the RBD of the original Covid-19 strain. This increased binding affinity of the Omicron variant is responsible for its increased internalization and infectivity. Purpose: In the present study, the impact of Coronil, a tri-herbal formulation of extracts from Withania somnifera, Tinospora cordifolia and Ocimum sanctum on the binding properties of Omicron SARS-CoV-2 variant spike proteins (S proteins) was investigated. Methods: Chemical composition of Coronil was determined by the Prominence-XR UHPLC system. The ELISA-based ACE2 binding inhibition assay was performed to delineate the effect of Coronil on the interaction between human ACE2 receptor and different Omicron variant S-proteins such as BA.4/BA5, XBB, BA.2.75.2, BA4.6/BF.7, BA.2.75.2, BQ.1.1 and a recently found spike protein variant JN.1 which is thought to emerge from BA.2.86. Results: Coronil showed a dose-dependent inhibitory effect on the interactions between ACE2 and receptor binding domains (RBD) of all variants of S-proteins evaluated in this study including the recently emerged, highly transmissible variant spike protein JN.1. Although, Coronil significantly reduced the binding percentage in almost all the variant spike proteins, the maximum inhibition was achieved against BA.4/BA.5 where it inhibited the S protein – ACE2 interaction even at a low concentration of 3 µg/ml (16.6 %). This binding inhibition was further increased to 60.3 and 84.3 % at 100 and 300 µg/ml respectively. Conclusion: This capability of Coronil to inhibit the binding of S-protein variants with ACE2 receptor may interfere with viral binding and internalization resulting in reduced infectivity of these Omicron spike protein variants. Overall, our data underscores the potential of Coronil in combating the various newly emerged Omicron spike protein variants. These findings may provide a basis for further studies of Coronil for its clinical effectiveness against these Omicron variants.
format Article
id doaj-art-47687b0fd5ce45c09d9510e2e4d039d7
institution Kabale University
issn 2667-0313
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Phytomedicine Plus
spelling doaj-art-47687b0fd5ce45c09d9510e2e4d039d72025-02-10T04:35:12ZengElsevierPhytomedicine Plus2667-03132025-02-0151100705Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptorAcharya Balkrishna0Rishabh Dev1Sandeep Kumar2Anurag Varshney3Drug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar, 249405, Uttarakhand, India; Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Roorkee-Haridwar Road, Haridwar, 249405, Uttarakhand, India; Patanjali Yog Peeth (UK) Trust, 40 Lambhill Street Kinning Park, Glasgow, G411AU, UK; Patanjali Yog Peeth Nepal, Budhanilkanth Metropolitan Wada No.8, Mandikatar, Kathmandu, NepalDrug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar, 249405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar, 249405, Uttarakhand, IndiaDrug Discovery and Development Division, Patanjali Research Foundation, NH-58, Haridwar, 249405, Uttarakhand, India; Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Roorkee-Haridwar Road, Haridwar, 249405, Uttarakhand, India; Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, 110067, India; Corresponding author.Background: Accumulating evidence suggests that the receptor binding domain (RBD) of the SARS-CoV-2 Omicron variant has several times more binding affinity to the human angiotensin-converting enzyme 2 (ACE2) receptor compared to the RBD of the original Covid-19 strain. This increased binding affinity of the Omicron variant is responsible for its increased internalization and infectivity. Purpose: In the present study, the impact of Coronil, a tri-herbal formulation of extracts from Withania somnifera, Tinospora cordifolia and Ocimum sanctum on the binding properties of Omicron SARS-CoV-2 variant spike proteins (S proteins) was investigated. Methods: Chemical composition of Coronil was determined by the Prominence-XR UHPLC system. The ELISA-based ACE2 binding inhibition assay was performed to delineate the effect of Coronil on the interaction between human ACE2 receptor and different Omicron variant S-proteins such as BA.4/BA5, XBB, BA.2.75.2, BA4.6/BF.7, BA.2.75.2, BQ.1.1 and a recently found spike protein variant JN.1 which is thought to emerge from BA.2.86. Results: Coronil showed a dose-dependent inhibitory effect on the interactions between ACE2 and receptor binding domains (RBD) of all variants of S-proteins evaluated in this study including the recently emerged, highly transmissible variant spike protein JN.1. Although, Coronil significantly reduced the binding percentage in almost all the variant spike proteins, the maximum inhibition was achieved against BA.4/BA.5 where it inhibited the S protein – ACE2 interaction even at a low concentration of 3 µg/ml (16.6 %). This binding inhibition was further increased to 60.3 and 84.3 % at 100 and 300 µg/ml respectively. Conclusion: This capability of Coronil to inhibit the binding of S-protein variants with ACE2 receptor may interfere with viral binding and internalization resulting in reduced infectivity of these Omicron spike protein variants. Overall, our data underscores the potential of Coronil in combating the various newly emerged Omicron spike protein variants. These findings may provide a basis for further studies of Coronil for its clinical effectiveness against these Omicron variants.http://www.sciencedirect.com/science/article/pii/S2667031324001799CoronilSARS-CoV-2OmicronVariant spike proteinACE2RBD
spellingShingle Acharya Balkrishna
Rishabh Dev
Sandeep Kumar
Anurag Varshney
Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
Phytomedicine Plus
Coronil
SARS-CoV-2
Omicron
Variant spike protein
ACE2
RBD
title Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
title_full Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
title_fullStr Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
title_full_unstemmed Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
title_short Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
title_sort coronil effectively inhibits the interaction of clinically relevant omicron mutants of sars cov 2 spike proteins with human ace2 receptor
topic Coronil
SARS-CoV-2
Omicron
Variant spike protein
ACE2
RBD
url http://www.sciencedirect.com/science/article/pii/S2667031324001799
work_keys_str_mv AT acharyabalkrishna coronileffectivelyinhibitstheinteractionofclinicallyrelevantomicronmutantsofsarscov2spikeproteinswithhumanace2receptor
AT rishabhdev coronileffectivelyinhibitstheinteractionofclinicallyrelevantomicronmutantsofsarscov2spikeproteinswithhumanace2receptor
AT sandeepkumar coronileffectivelyinhibitstheinteractionofclinicallyrelevantomicronmutantsofsarscov2spikeproteinswithhumanace2receptor
AT anuragvarshney coronileffectivelyinhibitstheinteractionofclinicallyrelevantomicronmutantsofsarscov2spikeproteinswithhumanace2receptor